Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
REGN — frequently asked questions
Is Regeneron Pharmaceuticals Inc. overvalued?
In our latest published analysis dated 2026-05-10, REGN looks meaningfully undervalued. The price recorded at analysis is USD 715 versus our fair value of USD 1.210; the high endpoint is presented separately as potential value of USD 1.505. That implies roughly 69.2% upside to fair value at that date.
Our latest published report, analyzed 2026-05-10, gives REGN a fair value of USD 1.210 and a potential value of USD 1.505. The conclusion is triangulated across multiple valuation models and weighted by reliability for Regeneron Pharmaceuticals Inc.'s archetype; it is a dated research output, not a live price.
Should I buy REGN now?
Our latest published rating for REGN, analyzed 2026-05-10, is Strong Buy. Regeneron Pharmaceuticals Inc. looks meaningfully undervalued at the analysis-date price of USD 715 versus fair value of USD 1.210; potential value is USD 1.505. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for REGN?
The dedicated bear-case section in our report analyzed 2026-05-10 documents Regeneron Pharmaceuticals Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is REGN's rating?
Our latest published rating for REGN, analyzed 2026-05-10, is Strong Buy, with a published moat assessment of 9/10 (Wide). It reflects our fair value of USD 1.210, the potential value of USD 1.505, and the price recorded at analysis (USD 715).
Engelse bron wordt weergegeven terwijl we vertalen
Dit rapport is nog niet vertaald. Vernieuw over een paar minuten zodra de vertaalwachtrij is bijgewerkt.
§1 SamenvattingEN
Antwoord in 30 secondenStrong Buy
Koers versus waarde
Koers
$714.89
Reële waarde
$1,209.72
Potentiële waarde
$1,505.07
Per
Koersdatum niet vastgelegd
Waarom het kan werken
Bull: Dupixent dominates the immunology space longer than anticipated, and high-dose Eylea proves impenetrable to biosimilar erosion.
Wat onze visie zou veranderen
High-Dose Eylea Fails to Defend Share: Vabysmo and early biosimilars rapidly erode Eylea's market dominance, cratering ophthalmology revenues before pipeline assets mature.
Regeneron is a high-quality mature biotechnology compounder with a strong core commercial portfolio (Dupixent, Eylea) and a proven R&D engine. Elevated near-term investments in pipeline and commercial capabilities have compressed margins, but offer a clear runway for long-term growth and diversification beyond its legacy blockbusters.
Regeneron is a high-quality mature biotechnology compounder with a strong core commercial portfolio (Dupixent, Eylea) and a proven R&D engine. Elevated near-term investments in pipeline and commercial capabilities have compressed margins, but offer a clear runway for long-term growth and diversification beyond its legacy blockbusters.
Patented core commercial assets in
Patented core commercial assets in Dupixent and Eylea generating sticky, recurring revenues.
VelociSuite R&D engine allowing highly
VelociSuite R&D engine allowing highly efficient discovery and commercialization timelines.
Cycle upside
Biotech enters a period of high M&A and pipeline validation; targeted biologics gain widespread formulary access and favorable pricing dynamics.
Huisaanbeveling
Strong Buy. The downside is fundamentally fully priced in, while the long-term compounder cash profile remains robust and highly intact.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
§2 BerenscenarioEN
In a severe downside scenario, Regeneron faces simultaneous shocks: Eylea loses material share to Vabysmo and biosimilars, Dupixent growth sharply decelerates, and pipeline failures force a structural reset in operating margins below 25%. Even under these dire conditions, baseline FCFF generation anchors intrinsic value near $917, indicating the downside is already heavily priced in.
Dupixent hits an earlier-than-expected growth wall.
Operating margins structurally trapped below 25% due to pipeline failures.
In a downside event where core assets erode rapidly and R&D fails to deliver, the stock still holds a baseline value of $917, highlighting the massive margin of safety currently priced into the $714 level.
Hoe deze these kan breken
High-Dose Eylea Fails to Defend Share
Low
Vabysmo and early biosimilars rapidly erode Eylea's market dominance, cratering ophthalmology revenues before pipeline assets mature.
FV impact
-25%
Dupixent Growth Wall
Medium
Dupixent matures faster than expected and label expansions underperform, halting the company's primary top-line engine.
FV impact
-15%
Vroege waarschuwingssignalen om te volgen
De vijf ontwikkelingen die onze beleggingsthese zouden verzwakken.
01
Eylea High-Dose Conversion Adoption
Failure of high-dose formulation to defend market share against biosimilars and competing bispecific therapies accelerates revenue erosion across core ophthalmology franchises, severely diminishing commercial cash generation.
Huidig:Baseline adoption as of 2026-05-10
Waarschuwing alsStalls below 50.0% conversion rate across eligible patient populations over any twelve-month measurement window
02
§3 ConcurrentievoordeelEN
Wide
Patented core commercial assets in Dupixent and Eylea generating sticky, recurring revenues.
VelociSuite R&D engine allowing highly efficient discovery and commercialization timelines.
Scale advantages in manufacturing and clinical trial execution versus smaller biopharma peers.
Economische winst
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
9/ 10
Wide
Sources of advantage
01Patented core commercial assets in Dupixent and Eylea generating sticky, recurri — Patented core commercial assets in Dupixent and Eylea generating sticky, recurring revenues.Wide
02VelociSuite R&D engine allowing highly efficient discovery and commercialization — VelociSuite R&D engine allowing highly efficient discovery and commercialization timelines.Wide
03Scale advantages in manufacturing and clinical trial execution versus smaller bi — Scale advantages in manufacturing and clinical trial execution versus smaller biopharma peers.Wide
Bekende bedreigingen voor het concurrentievoordeel
Bedreiging
Ernst
Tijdlijn
Beperking
Approaching patent cliffs and high-dose Eylea biosimilar threats.
medium
Monitor
Monitor the threat against the report checkpoints.
Competition from Roche/Genentech and targeted therapies like Vabysmo.
Dupixent dominates the immunology space longer than anticipated, and high-dose Eylea proves impenetrable to biosimilar erosion. Operating leverage drives margins past 35%, yielding an intrinsic value of $1,505.
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
Conform
Hold
Trigger: In-line results
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
Gemist
Reassess
Trigger: Downside surprise
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
Winstkwaliteit
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
Te volgen metrieken vóór publicatie
01
Metriek:
Eylea High-Dose Conversion Adoption
HuidigBaseline adoption as of 2026-05-10
Waarom het ertoe doet
Warning level: Stalls below 50.0% conversion rate across eligible patient populations over any twelve-month measurement window. Failure of high-dose formulation to defend market share against biosimilars and competing bispecific therapies accelerates revenue erosion across core ophthalmology franchises, severely diminishing commercial cash generation.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
Meest recente omzet14,3 mld.Omzet-CAGR +5,6%
Operationele marge25,8%5 boekjaarperioden
Meest recente vrije kasstroom3,8 mld.FY2025
Netto-kas412,2 mln.FY2025
Uitsplitsing van de resultatenrekeningHoe bedrijfsschaal wordt omgezet in gerapporteerde winst.
StockMarketAgent.AI
Omzet14,3 mld.Kostprijs van de omzet−2,1 mld.Brutowinst12,2 mld.Bedrijfskosten−8,5 mld.Bedrijfsresultaat3,7 mld.Niet-operationele posten en belastingen+802,9 mln.Nettowinst4,5 mld.
Financiële historische gegevens
Omzet
14.342.900.000
Kostprijs van de omzet
2.100.700.000
Brutowinst
12.242.200.000
Bedrijfskosten
8.540.200.000
Bedrijfsresultaat
3.702.000.000
Niet-operationele posten en belastingen
802.900.000
Nettowinst
4.504.900.000
Momentopname van de balansHoe de gerapporteerde activa in de geselecteerde periode worden aangehouden en gefinancierd.
REGN trades at 13.3x forward earnings against a peer median of 19.9x; EV/EBITDA of 15.2x against a peer median of 20.8x; 6 peers.
§10 Sector & cyclusEN
Cyclusfase
Expansion
Current phase requires intensive capital deployment into next-gen pipeline indications to bridge the gap before legacy asset patent cliffs arrive.
Bullencyclus
Biotech enters a period of high M&A and pipeline validation; targeted biologics gain widespread formulary access and favorable pricing dynamics.
Berencyclus
Regulatory pricing pressures compound with aggressive biosimilar substitution, severely discounting terminal multiples across mature biopharma.
Positionering
Current phase requires intensive capital deployment into next-gen pipeline indications to bridge the gap before legacy asset patent cliffs arrive.
§11 PositiebeheerEN
Positiegrootte
Core holding for large-cap growth allocations. Sizing should confidently reflect the robust margin of safety.
Risico
Trim exposure if shares approach the $1,200 fair value mid-point, or if high-dose Eylea fails to retain 50%+ share over a 12-month trailing period.
Entree-tranches
Niveau
Actie
Waarom
Current / pullbacks
Accumulate aggressively at current levels ($714), as the market is overly penalizing transient R&D investments.
Accumulate aggressively at current levels ($714), as the market is overly penalizing transient R&D investments.
Exit-tranches
Niveau
Actie
Thesis break
Trim exposure if shares approach the $1,200 fair value mid-point, or if high-dose Eylea fails to retain 50%+ share over a 12-month trailing period.
§12 BeleggersperspectievenEN
Bull view
Buy
Strong Buy. Regeneron is a high-quality mature compounder trading at a severe discount. Current pricing implies a nonsensical negative terminal growth rate, offering 69% upside to our $1,210 intrinsic value midpoint.
Base view
Buy
The 38.2% gap versus the $875.31 internal valuation cross-checks underscores a myopic market fixation on transient R&D spending and peak patent cliff fears, completely ignoring the underlying cash-generation power of VelociSuite.
§14 EindaanbevelingEN
Actie
Sterk kopen
Strong Buy. Regeneron is a high-quality mature compounder trading at a severe discount. Current pricing implies a nonsensical negative terminal growth rate, offering 69% upside to our $1,210 intrinsic value midpoint.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
A permanent reduction in operating margins highlights structural cost inflation and heavier commercialization overhead, limiting operational leverage and depressing long-term free cash flow yield.
Huidig:25.8% for the period ended 2025-12-31
Waarschuwing alsCompresses below 25.0% over any trailing twelve-month period
04
Late-Stage Clinical Asset Development
Repeated late-stage development setbacks in core oncology programs impair the research pipeline conversion thesis, destroying heavy capitalized investments without generating replacement revenue streams for maturing biologics.
Huidig:$5.8B annual R&D spend as of 2026-05-10
Waarschuwing alsFiled clinical suspension or primary endpoint failure in two or more Phase 3 oncology trials within a 24-month window
A structural breakdown in capital returns below double digits confirms that massive research outlays are failing to generate adequate economic profits, impairing corporate compounding quality.
Huidig:12.3% as of 2026-05-10
Waarschuwing alsBreaks below 10.0% as of any annual measurement date
Monitor
Monitor the threat against the report checkpoints.
Concentration risk given outsized revenue contribution from Dupixent.
medium
Monitor
Monitor the threat against the report checkpoints.
Our baseline assumes a successful transition from legacy assets to next-gen indications. Margins normalize to 30% as peak R&D spending subsides, anchoring fair value at $1,210 and bridging the gap from overly pessimistic internal valuation cross-checks.
Warning level: Compresses below 25.0% over any trailing twelve-month period. A permanent reduction in operating margins highlights structural cost inflation and heavier commercialization overhead, limiting operational leverage and depressing long-term free cash flow yield.
04
Metriek:
Late-Stage Clinical Asset Development
Huidig$5.8B annual R&D spend as of 2026-05-10
Waarom het ertoe doet
Warning level: Filed clinical suspension or primary endpoint failure in two or more Phase 3 oncology trials within a 24-month window. Repeated late-stage development setbacks in core oncology programs impair the research pipeline conversion thesis, destroying heavy capitalized investments without generating replacement revenue streams for maturing biologics.
Warning level: Breaks below 10.0% as of any annual measurement date. A structural breakdown in capital returns below double digits confirms that massive research outlays are failing to generate adequate economic profits, impairing corporate compounding quality.
